On the Horizon: Asciminib, a New Drug for Treating R/R CML








Posted on: December 14, 2020


Category: News , Hematology-Oncology

On the Horizon: Asciminib, a New Drug for Treating R/R CML



A first-in-class STAMP inhibitor, asciminib, shows better efficacy than bosutinib in patients with relapsed/refractory chronic myeloid leukemia in the chronic phase.
Medscape Medical News


Tags: News , Hematology-Oncology


Welcome to the healthcare-only HIPAA - GDPR compliant cloud. Exclusively hosted on a HPC environment!

Learn more or start today by choosing your secure HIPAA - GDPR compliant server's Operating System bellow and pick the package that's best for you.

BIPmd makes it simple to launch in the cloud and scale up as you grow – whether you’re running one virtual machine, thousand or more.



Windows VPS options and add ons
Linux VPS options and add ons

Looking for a custom solution?

Our technicians can provide you with the best custom-made solutionss on the market, no matter whether you're a small business or large enterprise.

Get in touch